[1] Temple JL,Cordero P,Li J,et al. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci,2016,17:E947.
[2] 徐燕华,欧强.非酒精性脂肪性肝炎相关肝细胞癌研究进展.肝脏,2016,21:1074-1076.
[3] Ballestri S,Lonardo A,Bonapace S,et al.Risk of cardiovascular,cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.World J Gastroenterol,2014,20:1724-1745.
[4] Deng H,Wang CL,Lai J,et al.Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients.Hepat Mon,2016,16:e40263.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版).中华肝脏病杂志,2010,18:163-166.
[6] Benedict M,Zhang X.Non-alcoholic fatty liver disease: An expanded review.World J Hepatol,2017,9:715-732.
[7] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease: the major impact of China.Hepatology, 2014,60:2099-2108.
[8] Cheah MC,McCullough AJ,Goh GB.Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease.J Clin Transl Hepatol,2017,5:261-271.
[9] Wang CY,Lu W,Hu DS,et al.Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World J Gastroenterol,2014,20:10585-10590.
[10] Shen F,Zheng RD,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol,2014,20:4702-4711.
[11] 杨硕,吕栋,王天懿,等.FibroTouch○R脂肪衰减参数对非酒精性脂肪性肝病患者肝脏脂肪变程度的诊断价值.实用肝脏病杂志,2016,19:50-54.
[12] Lückhoff HK,Kruger FC,Kotze MJ.Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol,2015,7:1192-1208. |
